Business News
Financial news, mergers and acquisitions, partnerships, and alliances.
BioArctic Doses First Parkinson's Patient in Trial of Alpha-Synuclein-Targeting Drug
Exidavnemab is a monoclonal antibody designed to eliminate aggregated clumps of the protein biomarker and slow progression of Parkinson's disease.
In particular, patients who had fewer than 10 annual vaso-occlusive events before the gene therapy were more likely to have none after treatment.
Denali Therapeutics Doses First LRRK2 Parkinson's Patient in Phase IIa Trial
BIIB122, previously known as DNL151, is a small molecule designed to inhibit LRRK2, mutations in which are the most common cause of inherited Parkinson's.
Updated NCCN Guidelines Adjust Ratings for Prostate Cancer Genetic Tests
The newest version ups its endorsement of somatic genomic testing to "recommended" for advanced cancers and shifts its recommendations on early-stage risk assays.
Solid Biosciences Inks Deal With Mayo Clinic to Develop Cardiac Gene Therapies
The Mayo Clinic will be responsible for R&D through IND-enabling studies, and Solid will have the option to pursue continued development.